Clinical Trials Logo

Lymphoma, Large B-Cell, Diffuse clinical trials

View clinical trials related to Lymphoma, Large B-Cell, Diffuse.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05619367 Available - Clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)

A Compassionate Use (CU) Program of Odronextamab

Start date: n/a
Phase:
Study type: Expanded Access

Provide compassionate use of odronextamab

NCT ID: NCT04400591 Available - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is manufactured the drug does not pass all the testing results to be called lisocabtagene maraleucel. When this happens the drug is called nonconforming lisocabtagene maraleucel. The expanded access protocol will be used to allow subjects to receive nonconforming lisocabtagene maraleucel only if the potential benefit is better than the potential risk. This expanded access protocol is restricted to those subjects who were prescribed lisocabtagene maraleucel as part of their routine care. Subjects will first receive a lymphodepleting chemotherapy regimen and then be treated with nonconforming lisocabtagene maraleucel as the treatment plan.

NCT ID: NCT03601442 Available - Clinical trials for Acute Lymphoblastic Leukemia (ALL)

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Start date: n/a
Phase:
Study type: Expanded Access

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.